What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?

Ji Guang Wang, Yook Chin Chia, Chen Huan Chen, Sungha Park, Satoshi Hoshide, Naoko Tomitani, Tomoyuki Kabutoya, Jinho Shin, Yuda Turana, Arieska Ann Soenarta, Jam Chin Tay, Peera Buranakitjaroen, Jennifer Nailes, Huynh Van Minh, Saulat Siddique, Jorge Sison, Guru Prasad Sogunuru, Apichard Sukonthasarn, Boon Wee Teo, Narsingh VermaYu Qing Zhang, Tzung Dau Wang, Kazuomi Kario

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The new Chinese hypertension guideline comprehensively covers almost all major aspects in the management of hypertension. In this new guideline, hypertension remains defined as a systolic/diastolic blood pressure of at least 140/90 mm Hg. For risk assessment, a qualitative approach is used similarly as in previous Chinese guidelines according to the blood pressure level and the presence or absence of other risk factors, target organ damage, cardiovascular complications, and comorbid diseases. The therapeutic target is 140/90 mm Hg in general, and if tolerated, especially in high-risk patients, can be more stringent, that is, 130/80 mm Hg. However, a less stringent target, that is, 150/90 mm Hg, is used in the younger (65-79 years, if tolerated, 140/90 mm Hg) and older elderly (≥80 years). Five classes of antihypertensive drugs, including β-blockers, can be used either in initial monotherapy or combination. The guideline also provided information on the management of hypertension in several special groups of patients and in the presence of secondary causes of hypertension. To implement the guideline recommendations, several nationwide hypertension control initiatives are being undertaken with new technology. The new technological platforms hopefully will help improve the management of hypertension and generate scientific evidence for future hypertension guidelines, including a possible Asian hypertension guideline in the near future.

Original languageEnglish
Pages (from-to)363-368
Number of pages6
JournalJournal of Clinical Hypertension
Volume22
Issue number3
DOIs
Publication statusPublished - 2020 Mar 1

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?'. Together they form a unique fingerprint.

  • Cite this

    Wang, J. G., Chia, Y. C., Chen, C. H., Park, S., Hoshide, S., Tomitani, N., Kabutoya, T., Shin, J., Turana, Y., Soenarta, A. A., Tay, J. C., Buranakitjaroen, P., Nailes, J., Van Minh, H., Siddique, S., Sison, J., Sogunuru, G. P., Sukonthasarn, A., Teo, B. W., ... Kario, K. (2020). What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia? Journal of Clinical Hypertension, 22(3), 363-368. https://doi.org/10.1111/jch.13803